Valuation: Daxor Corporation

Market Cap 60.6M 52.34M 49.19M 44.73M 84.1M 5.8B 85.49M 576M 225M 2.9B 228M 223M 9.64B P/E 2026 *
-49.5x
P/E 2027 * -347x
Enterprise Value 60.6M 52.34M 49.19M 44.73M 84.1M 5.8B 85.49M 576M 225M 2.9B 228M 223M 9.64B EV / Sales 2026 *
5.09x
EV / Sales 2027 * 2.91x
Free-Float
46.74%
Yield 2026 *
-
Yield 2027 * -
1 week 10.05
Extreme 10.05
10.45
1 month 10.05
Extreme 10.05
11.97
3 years 6.55
Extreme 6.55
14.76
5 years 6.55
Extreme 6.55
14.76
10 years 3.4
Extreme 3.4001
24.08
Manager TitleAgeSince
Chief Executive Officer 56 01/01/2013
Director of Finance/CFO 69 28/09/2018
Chief Tech/Sci/R&D Officer - 05/06/2024
Director TitleAgeSince
Director/Board Member 91 01/01/1989
Chairman 56 14/02/2017
Director/Board Member 70 22/06/2016
Change 5-day change 1-year change 3-year change Capi.($)
+1.96%+2.87% - - 60.6M
+0.70%+1.10%+29.60%+125.44% 15.76B
+0.52%+1.25%+63.41%+173.77% 13.32B
+1.81%+0.66%-6.24%+32.68% 9.3B
+0.77%+2.18%+43.69%+152.15% 8.23B
-0.76%-2.05%-17.97%-15.19% 7.27B
-0.04%-0.07%+17.17%+49.31% 6.68B
-0.26%-0.39%+9.74%+27.67% 4.79B
+0.64%+1.20%+11.81%+9.69% 4.14B
+0.20%+2.57% - - 4.03B
Average +0.40%+1.28%+18.90%+69.44% 8.17B
Weighted average by Cap. +0.51%+1.69%+24.36%+89.80%

Financials

2026 *2027 *
Net sales 11.9M 10.28M 9.66M 8.78M 16.51M 1.14B 16.79M 113M 44.25M 570M 44.68M 43.71M 1.89B 20.8M 17.96M 16.88M 15.35M 28.86M 1.99B 29.34M 198M 77.34M 996M 78.09M 76.4M 3.31B
Net income -1.2M -1.04M -974K -886K -1.67M -115M -1.69M -11.41M -4.46M -57.46M -4.51M -4.41M -191M -200K -173K -162K -148K -278K -19.12M -282K -1.9M -744K -9.58M -751K -735K -31.83M
Net Debt - -
Logo Daxor Corporation
Daxor Corporation is a diversified, closed-end management investment company. Its focus and operations are as a medical device manufacturing, company. It specializes in blood volume measurement technology focused on blood volume testing innovation. It markets the Blood Volume Analyzer (BVA)-100, the diagnostic blood test cleared by the FDA to provide objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000 tests have been performed at hospital centers across the United States, enhancing hospital performance metrics in a range of surgical and medical conditions, including reducing mortality and readmissions in heart failure and critical care. Its facility provides on-demand, next day blood volume analysis results. It has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the United States Department of Defense.
Employees
-
Date Price Change Volume
14/08/26 US$0.000000 -100.00% 187
13/08/26 US$10.40 +1.96% 530
12/08/26 US$10.20 -0.39% 2,558
11/08/26 US$10.24 -2.01% 4,069
10/08/26 US$10.45 +3.36% 931
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
10.40USD
Average target price
22.50USD
Spread / Average Target
+116.35%

Quarterly revenue - Rate of surprise